CureMD Launches Innovative Cardio Risk Assessment TechnologyNew York, NY. 1/30/2015
CureMD has launched an innovative, non-invasive cardio risk assessment technology that efficiently measures cardiovascular health for a range of patients.p>
By using the technology, CureMD subscribers can analyze pulse wave velocity and measure vascular elasticity and stiffness in less than 5 minutes. As a plus, clinical staff will be paid for the time spent on each patient with at least two chronic conditions through the updated Medicare Physician Fee Schedule
"We are proud to bring tomorrow’s disruptive technology today," said Bilal Hashmat, CEO at CureMD. "Cardio wave Analyzer brings life saving technology to primary care physicians that maximizes remote care benefits to increase the value of care delivery, monitor time spent on each patient and reduce healthcare costs."
This technology uses a finger probe to observe changes in blood flow, velocity and profile throughout the pulse wave. It can quickly detect arterial wall elasticity, cardiovascular diseases, biological age of arteries and measure therapeutic intervention effectiveness.
Patients suffering from diabetes, high blood pressure, high cholesterol, dizziness, lightheadedness, shortness of breath and with recurrent lower back pain will be able to benefit massively from this innovative solution.
The solution is available for CureMD subscribers at an affordable price. For more information, please visit www.curemd.com/cardiowave-analyzer.asp